⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17108528 | 1.00 | — | — | |
| SCHEMBL17108529 | 1.00 | — | — | |
| SCHEMBL9963376 | 0.83 | — | — | |
| SCHEMBL681681 | 0.83 | — | — | |
| SCHEMBL23365920 | 0.83 | HRH3 (0.34) | — | |
| SCHEMBL89043 | 0.81 | KDM4E (0.42) | — | |
| SCHEMBL6903141 | 0.81 | KDM4E (0.42) | — | |
| SCHEMBL681878 | 0.81 | KDM4E (0.42) | — | |
| SCHEMBL20162000 | 0.81 | L3MBTL1 (0.33) | — | |
| SCHEMBL17449612 | 0.79 | L3MBTL1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123966-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | THIRD HARMONIC BIO, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023081840-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230065463-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210171554-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| EP-2773634-B1 | ROD-LIKE HEPATITIS C VIRUS INHIBITORS CONTAINING THE FRAGEMENT {2-[4-(BIPHENYL-4-YL)-1H-IMIDAZO-2-YL]PYRROLIDINE-1-CARBONLYMETHYL}AMINE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9850225-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
| US-9492460-B2 | Carbazole compounds useful as bromodomain inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150291549-A1 | Compounds Useful as Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-15 | — | — | US | disclosed |
| US-20140256700-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-11 | — | — | US | disclosed |
| WO-2014037340-A1 | USE OF SUBSTITUTED 2-AMIDOBENZIMIDAZOLES, 2-AMIDOBENZOXAZOLES AND 2-AMIDOBENZOTHIAZOLES OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-03-13 | — | — | WO | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8106034-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-1467989-B1 | PROLINE COMPOUNDS AS NS3-SERINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF HEPATITIS C VIRUS INFECTION | SCHERING CORP (US) | 2009-09-23 | — | — | EP | disclosed |